David M OMalley
Overview
Explore the profile of David M OMalley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
199
Citations
6775
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chalif J, Khadraoui W, Hays J, Copeland L, Vargas R, OMalley D, et al.
Int J Gynecol Cancer
. 2025 Mar;
:101693.
PMID: 40024811
Objective: This study aimed to assess the readability of patient-facing gynecologic cancer clinical trial information on National Cancer Institute-Designated Comprehensive Cancer Center (NCI-CCCs) websites. Methods: This was a cross-sectional analysis...
2.
Vergote I, Copeland L, Van Gorp T, Laenen A, Scambia G, Thaker P, et al.
Eur J Cancer
. 2025 Feb;
219:115306.
PMID: 40010134
Purpose: Tumor Treating Fields (TTFields) are electric fields that disrupt processes critical for cancer cell viability and tumor progression. The pivotal, phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 study evaluated efficacy and safety of...
3.
Marabelle A, OMalley D, Hendifar A, Ascierto P, Motola-Kuba D, Penel N, et al.
Nat Cancer
. 2025 Feb;
6(2):253-258.
PMID: 39979665
The phase 2 trial KEYNOTE-158 ( NCT02628067 ) evaluated pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient (MSI-H/dMMR) noncolorectal tumors. With 373 participants (95% with baseline MSI/dMMR documentation) and 4.5 years of follow-up,...
4.
OMalley D, Bariani G, Cassier P, Marabelle A, Hansen A, Acosta A, et al.
Gynecol Oncol
. 2025 Jan;
193:130-135.
PMID: 39847999
Objective: We report updated results with longer follow-up in patients with MSI-H/dMMR endometrial cancer (EC) in cohort D (advanced EC of any MSI/dMMR status) and cohort K (any MSI-H/dMMR advanced...
5.
Okines A, Curigliano G, Mizuno N, Oh D, Rorive A, Soliman H, et al.
Nat Med
. 2025 Jan;
PMID: 39825152
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer....
6.
Matei D, Enserro D, Randall M, Mutch D, Small W, DiSilvestro P, et al.
J Clin Oncol
. 2024 Dec;
43(9):1055-1060.
PMID: 39700442
This randomized phase III trial aimed to determine whether treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for four cycles (chemoradiotherapy [C-RT]) increased recurrence-free survival (RFS) and...
7.
Graybill W, Vergote I, Pothuri B, Anttila M, OMalley D, Lorusso D, et al.
J Comp Eff Res
. 2024 Dec;
14(1):e240133.
PMID: 39641537
To understand the impact of the niraparib individualized starting dose (ISD), compared with fixed starting dose (FSD), on the cost of hematologic adverse event (AE) management from a US payer...
8.
Powell M, Cibula D, OMalley D, Boere I, Shahin M, Savarese A, et al.
Gynecol Oncol
. 2024 Nov;
192():40-49.
PMID: 39531903
Objectives: Part 1 of the RUBY trial (NCT03981796) demonstrated improved survival in patients with primary advanced or recurrent endometrial cancer (EC) treated with dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel....
9.
Moore K, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, et al.
Gynecol Oncol
. 2024 Oct;
191:249-258.
PMID: 39461270
Objective: Mirvetuximab soravtansine-gynx (MIRV) is a novel antibody-drug conjugate targeting folate receptor alpha (FRα), which is overexpressed in epithelial ovarian cancer (EOC), with limited expression on normal tissues. This integrated...
10.
Sakaue T, Dorayappan K, Zingarelli R, Khadraoui W, Anbalagan M, Wallbillich J, et al.
Oncogene
. 2024 Oct;
43(49):3586-3597.
PMID: 39414985
Endometrial cancer (EC) is the leading gynecologic malignancy in the United States with obesity implicated in 57% of cases. This research investigates the molecular complexities of extracellular vesicles (EV) secretion...